HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drugs t...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlam, Ilana, Swain, Sandra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137941/
https://www.ncbi.nlm.nih.gov/pubmed/34016991
http://dx.doi.org/10.1038/s41523-021-00265-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137941/
https://www.ncbi.nlm.nih.gov/pubmed/34016991
http://dx.doi.org/10.1038/s41523-021-00265-1

Ejemplares similares